Valuation: PREDILIFE

Market Cap 3.71M 4.22M 3.5M 3.19M 5.97M 405M 6.01M 41.96M 16.26M 206M 15.83M 15.49M 670M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 8.49M 9.65M 8M 7.3M 13.65M 926M 13.76M 96.01M 37.21M 471M 36.23M 35.44M 1.53B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day+1.95%
1 week-7.84%
Current month-16.07%
1 month-15.32%
3 months-60.83%
6 months-69.68%
Current year-68.77%
1 week 0.91
Extreme 0.91
0.98
1 month 0.91
Extreme 0.91
1.24
Current year 0.9
Extreme 0.9
4
1 year 0.9
Extreme 0.9
4
3 years 0.9
Extreme 0.9
24
5 years 0.9
Extreme 0.9
24
10 years 0.9
Extreme 0.9
24
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2003
Chief Tech/Sci/R&D Officer - 31/12/2006
General Counsel - 31/12/2015
Director TitleAgeSince
Chairman 56 31/12/2003
Director/Board Member 46 31/12/2017
Director/Board Member 58 31/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
27/07/23 Buy

Chief Executive Officer

1,200 0.0328%
23/03/22 Sell

Chief Executive Officer

3,000 0.0820%
09/03/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
+1.95%-7.84%-70.44%-81.92% 4.15M
+5.99%+7.78%+409.43%+121.77% 4.62B
+6.02%+3.57%+130.66%+483.23% 4.45B
+10.77%+19.65%+48.53%+116.02% 3.52B
+13.00%+13.06%+307.50%+701.17% 2.81B
+2.50%+20.93%-9.18%-15.52% 2.52B
-4.59%-3.62%+48.11% - 1.69B
-0.58%+0.89%+30.52%+61.14% 1.13B
+3.80%+5.23%+181.25%-20.31% 1.1B
+5.08%+3.98%-17.88%+84.39% 625M
Average +3.81%+5.61%+105.85%+161.11% 2.25B
Weighted average by Cap. +4.77%+8.26%+168.55%+247.96%

Financials

2024 2025
Net sales 493K 561K 465K 424K 793K 53.82M 799K 5.58M 2.16M 27.39M 2.11M 2.06M 89.14M 836K 950K 788K 719K 1.34M 91.21M 1.35M 9.46M 3.66M 46.42M 3.57M 3.49M 151M
Net income -4.26M -4.85M -4.02M -3.67M -6.86M -465M -6.91M -48.24M -18.7M -237M -18.2M -17.81M -771M -3.93M -4.47M -3.71M -3.38M -6.33M -429M -6.38M -44.51M -17.25M -219M -16.79M -16.43M -711M
Net Debt 3.54M 4.02M 3.34M 3.04M 5.69M 386M 5.74M 40.03M 15.51M 197M 15.1M 14.78M 640M 4.78M 5.43M 4.5M 4.11M 7.68M 521M 7.74M 54.05M 20.94M 265M 20.39M 19.95M 864M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
24/09/26 €0.9400 +1.95% 310
23/09/26 €0.9220 +1.32% 676
22/09/26 €0.9100 0.00% 250
21/09/26 €0.9100 -10.78% 90
18/09/26 €1.020 0.00% 2,258

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock